

ersonal use only

US FDA 510(k) Clearance for Orthocell's Flagship **Remplir™** Product

April 2025



ortho·cell

Disclaimer

This presentation prepared by Orthocell Ltd (“Company”) does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or

representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward-looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.


Remplir™ US FDA 510(k) Clearance

A Company
Defining Moment



US FDA 510(k) clearance

Received for its flagship Remplir nerve repair product. Clears the way to commercial distribution into the US which represents a US\$1.6 billion total addressable market¹



Major Revenue Inflection

Provides the catalyst to drive the Company towards breakeven and profitability within a foreseeable timeframe



Scaled Manufacturing Facility

Orthocell owns and controls its manufacturing process and is prepared to supply the US market, with an annual medical device capacity for > 100,000 units and significant inventory in place. Material capital costs associated with production ramp up have already been incurred.



Outsourced Logistics

Ready to fill sales orders from Day 1. Stock to be warehoused at Uniphar's GMP certified 65,000 square feet facility in the US with central coordination of warehousing, order processing, shipping, and customer service



Proven Sales Model

Pathway to market in the US in place and expanding. **Internal Sales, Marketing and Medical Education team combined with Distributor Network ready to roll out**



Strong Balance Sheet

Existing cash reserves of ~\$32 million² are sufficient to undertake the US roll out

1. USA nerve repair market size was estimated using referenced papers from both US and OUS databases and studies.

2. Cash at bank as at 26th March, 2025

ersonal use only

Remplir™
Redefining
Nerve Repair




Remplir™ Redefining Nerve Repair

Collagen nerve wrap used in the repair of peripheral nerve injuries. It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing.



Guiding predictable outcomes in peripheral nerve repair




- ✓ Exceptional handling characteristics
- ✓ Mimics epineurium (nerve outer layer)
- ✓ Reduces need for multiple sutures
- ✓ Returns nerve to pre-injured state



ersonal use only

Remplir™ Compelling Clinical Results

Patients regained voluntary muscle movement within 12 months, with increased muscle strength and range of motion at 24 months



Useful Function

Voluntary movement with improved strength and range of motion

Minimal Function

Voluntary movement restored, limited strength and range of movement

No Function

No voluntary movement

Final results

85% (23 of 27) of nerve repairs resulted in functional recovery of muscles controlled by the repaired nerve



We are now seeing a consistent return of arm and hand function following nerve transfer surgery with Remplir. Remplir is increasing the success rate and efficiency of nerve transfer surgery.

Leading Australian orthopaedic nerve specialist and clinical trial lead, **Dr Alex O'Beirne**

Remplir™ Indications

Remplir is a highly versatile product that delivers a single solution for either connecting severed nerves, protecting damaged nerves or capping amputated nerves



> 180 surgeons


now using the device in existing markets



> 150 hospitals


now supply the device to plastic reconstructive and orthopedic surgeons

Repair with Remplir™




CONNECT

Trauma: motor vehicle, power tool, surgical injuries, sports and military related accidents



PROTECT

Compression: blunt trauma, revisions surgeries (e.g. carpal/cubital tunnel)



CAP

Amputation: amputations, stump neuroma, mastectomies, schwannoma

Remplir™ US Peripheral Nerve Repair Trends

Suturing is still the most commonly performed procedure and considered to be the “gold standard” technique for peripheral nerve repair



Over 700,000¹ peripheral nerve repair procedures in the US per year, 90% undertaken using suture only method.

Suturing

- Technically difficult to achieve alignment and tensionless repair
- Induces foreign body reaction leading to chronic inflammation, fibrosis and scarring
- Can lead to suboptimal axonal regeneration and return of function and sensation



Success Rates 50-70%

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both US and OUS databases and studies

Remplir™ Significant US Market Opportunity

Clearance paves the way for Orthocell to commence commercial distribution into an estimated US\$1.6 billion total addressable nerve repair market¹ in the US alone




Remplir is not seeking to replace a current dominant market incumbent.
Devices are only used in ~10% of procedures.

Current devices are not widely adopted

- Materials are too rigid, challenging to deploy and make it difficult to manage size differences between nerve ends, leading to compression injuries or neuroma formation
- Fail to fully integrate into native tissue, leaving residual material that impairs the healing process
- Have not significantly improved the consistency of outcomes



Current devices



Remplir™



1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both US and OUS databases and studies

Remplir™ US Commercialisation Platform

Ready to fill sales orders from day 1



Manufacturing

Existing GMP facility in place
in Western Australia



Logistics / Shipping

US based central
warehousing, order
fulfillment, customer service



US Market Roll Out

Internal Sales and Med
Ed team combined with
Distributor Network



Remplir™

Manufacturing / Product Supply

Capacity in place to deliver the volumes through to company profitability

- Annual medical device production capacity of **100,000 units** in place at certified GMP facility in Western Australia
- **No near-term requirement** for increased production capacity
 - Already in production for Australia, New Zealand and Singapore
 - MDSAP, MDR quality standards
- Production ramp up underway in anticipation of US FDA approval with **significant inventory in place** (3-year shelf life)
- Plentiful raw material source, with **back up suppliers**





Logistics /
Shipping

Remplir™

Logistics / Shipping

On the ground logistics in the US to deliver into early sales orders

- Stable product for shipping, **no temperature control required**
- Stock to be warehoused at Uniphar's GMP certified **65,000 square feet facility in the US** with central coordination of warehousing, order processing, shipping, and customer service
- The facility is equipped with redundant power supply, environmental monitoring systems, and advanced inventory management, **ensuring compliance with FDA, ISO, and DSCSA regulations.**
- Orders received before 2:00 PM local time will be **shipped the same day** for a next day delivery





US Market
Roll Out

US Sales, Marketing and Medical Affairs Executives

Orthocell has appointed experienced US-based executives to drive the market launch and sales of Remplir



John Walker

Vice President – Sales

Mr Walker is a highly experienced sales executive, who has successfully led global product launches and sales strategies, most notably helping to lead the growth of nerve repair device sales at Axogen.



Phillip Edmondson

Vice President – Medical Affairs

Mr Edmondson is an award-winning medical affairs professional, who excels in creating product awareness, building advocacy and implementing successful medical education programs that contribute to sales growth.



Kevin Leach

Head of Marketing

Mr. Leach is a highly regarded senior marketing executive with extensive knowledge and experience in the development and commercialization of technologies for peripheral nerve regeneration and repair in the USA.




US Market
Roll Out

Remplir™ US Market Roll Out

6 months preparation activities already undertaken.
Pre-launch completed in advance of FDA approval

- Hybrid sales approach of in-house sales and medical education team combined with engagement of external distributors
- **Critical pre-launch activities to lay the foundation in anticipation of FDA approval completed:**
 - Strengthening panel of key opinion leaders
 - Influential hospital reference sites to drive early sales orders
 - Sales Distributors screened ready to commit, pending FDA approval
 - Sales training and Medical education programs ready to roll out pending FDA approval
 - Marketing collateral ready to roll out pending FDA approval
 - Reimbursement guidelines

Planned Structure



Remplir™ Pre-launch Completed

Orthocell successfully completed a pre-launch program at the 2025 IFSSH and IFSHT Triennial Congress in the US in advance of FDA approval. Attended by leading peripheral nerve surgeons from the US and other countries.

2025 IFSSH and IFSHT Triennial Congress
WASHINGTON, D.C. USA



2025 IFSSH and IFSHT Triennial Congress

International Federation of Societies for Surgery of the Hand
International Federation of Societies for Hand Therapy



Remplir™ Investment Highlights



Commercial-stage medical device company at **revenue inflection** point following US FDA approval for its flagship Remplir product with pre-launch completed



Best in class products for Bone, Nerve and Tendon repair approved in ten jurisdictions



Strengthened board with the appointments of highly experienced executives John Van Der Wielen, Professor Fiona Wood and Kim Beazley



~\$32M cash at bank, strengthened share register, share market momentum, well-funded for US roll out



Product margins retained in-house Manufacturing facility and all IP owned by the company

Upcoming Catalysts¹



Remplir™ Redefining nerve repair

US FDA market clearance and Pre-Launch	Achieved
Appoint US sales team	2Q CY25
Appoint US distributors	2Q CY25
US first sales	2Q CY25
EU+UK & Brazil submissions lodged	3Q / 4Q CY25



Striate+™ Growing better bone

Germany, Austria, Switzerland market launch	Achieved
Singapore product registration	Achieved
Brazil product registration	2Q CY25
Hong Kong submission lodged	2Q CY25

1. Timelines may be subject to change due to circumstances not under the Company's control

ersonal use only

Appendices

Corporate Snapshot

Highly Credentialed Board



Corporate Snapshot

Well funded beyond US market clearance of Remplir, supported by leading life science institutional investors

ASX: OCC Trading Information

Share Price (as @ 03rd March 2025) **\$1.44**

12 month low/high \$0.35/\$0.1.79

Shares outstanding 241M

Market Capitalisation ~\$347M

Cash (26 Mch) ~\$32M


Debt (26 Mch) Nil

Substantial Shareholders %

Founders & Management ~11%

Institutions & HNW's (Sankofa, Cerutti, Austral Capital, Thesis Asset Mgt, Private Portfolio Mgr's, FundBPO, Wyllie Group) ~14%

12 Month Share Price And Volume



~AU\$32m

Strong balance sheet,
no debt, no royalties

ersonal use only

Highly Credentialed Board

Recent appointments of John Van Der Wielen and Professor Fiona Wood AM places Orthocell in a strong position to drive its products into global markets and accelerate revenue growth



Mr John Van der Wielen
Independent Non-Executive Chairman

- 35+ years experience in international financial services including large funds management, insurance and private banking
- Former CEO of HBF with annual revenues over \$2B
- Extensive corporate strategy, institutional and strategic investor engagement and M&A transaction experience



Mr Paul Anderson
Founder and Managing Director

- 25+ years in regenerative medicine industry
- Former MD at Verigen, successfully commercialised cartilage repair cell therapy (MACI)
- Extensive experience in product development, navigating regulatory pathways, international market launches, medical education and sales force leadership



Dr Rravi I. Thadhani
Independent Non-Executive Director

- 30 years of specialist experience working in US healthcare sector – highly regarded executive, medical administrator and researcher
- Former professor of medicine at Harvard Medical School and chief academic officer at Mass General Brigham hospital, where he oversaw a \$2.3 billion research enterprise
- Extensive US regulatory experience and commercialisation of devices and therapeutics



Professor Fiona Wood AM
Non-Executive Director

- 30+ years experience as a plastic and reconstructive surgeon
- Inventor of RECELL “spray on skin” treatment, now supplied by Avita Medical Inc, a AU\$450M dual-listed company with operations in 30+ countries including the US
- Unrivalled track record in development and commercialisation of innovative regenerative medicine products.



Hon Kim Beazley AC
Independent Non-Executive Director

- Unrivalled experience engaging strategic partners in the US-highly regarded politician, executive and strategic adviser
- Former Australian US Ambassador and Governor of Western Australia, Deputy Prime Minister, and Minister for both Defence and Finance
- Extensive experience representing both public and private interests for Australia

ersonal use only



Authorised for release by
Co-Founder and Managing Director, Paul Anderson

Orthocell Limited
P: +61 8 9360 2888
E: paul.anderson@orthocell.com.au

orthocell.com